Your Source for Venture Capital and Private Equity Financings

Graviton Bioscience Lands New Funding

2024-01-02
NEW YORK, NY, Graviton Bioscience announced completion of financing from Enavate Sciences, a portfolio company of Patient Square Capital.
Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) announced completion of financing from Enavate Sciences, a portfolio company of Patient Square Capital. Proceeds from Enavate's investment will help to advance clinical development of GV101 and Graviton's pipeline of ROCK2 inhibitors to treat a range of serious fibrotic, inflammatory and neurologic conditions.

Graviton Bioscience is a clinical stage drug discovery and development company, dedicated to engineering and developing best-in-class therapeutics for treating CNS, autoimmune, fibrotic and other serious diseases where ROCK2 plays a pivotal role in pathology.¯ Graviton's first drug candidate GV101 is in clinical studies, with additional assets advancing through the preclinical pipeline. Leading the company is Dr. Samuel Waksal, the founder and former Chairman and CEO of Kadmon Pharmaceuticals (acquired by Sanofi) where he led the development of REZUROCK® (belumosudil), the first approved ROCK2 inhibitor. Dr. Waksal is also the founder and former CEO of ImClone Systems (acquired by Eli Lilly) and a founder of MeiraGTx.¯
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors